EGFR and non-small cell lung carcinoma: Randomized clinical trials to compare the efficacy of EGFR-TKIs or platinum-based compounds as first-line chemotherapy for patients with NSCLC harboring EGFR mutations [4]–[7] have demonstrated that NSCLC patients with EGFR mutations show a dramatic response to EGFR-TKIs and a longer PFS than those without EGFR mutations.